European Journal of Cancer

ABBREVIATIONS; 4ITLR (4-IN-THE-LUNG-RUN) AI (Artificial intelligence) CAC (Coronary artery calcification) COPD (Chronic obstructive pulmonary disease) FOV (Field of view) GP (General practitioner) IF (Incidental finding) LCS (Lung cancer screening) LDCT (Low-dose computed tomography) LHC (Lung Health Check) KEYWORDS Early detection of cancer Lung cancer screening Imaging Low-dose computed tomography Radiology Workload Lung Cardiovascular Public health Get full text access Log in, subscribe or...

Keywords Early onset colorectal cancer Europe epidemiology screening early detection survivorship risk factors health disparities Get full text access Log in, subscribe or purchase for full access. References 1. Bray, F. ∙ Laversanne, M. ∙ Sung, H. ... Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA: A Cancer Journal for Clinicians. 2024; 74:229-263 2. Hofseth, L.J. ∙ Hebert, J.R. ∙ Chanda, A. ...

Keywords Randomised controlled trials Risk of bias Clinical benefit Cancer drugs Cochrane Risk-of-Bias Tool 2.0 European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Get full text access Log in, subscribe or purchase for full access. References 1. Tannock, I.F. ∙ Amir, E. ∙ Booth, C.M. ... Relevance of randomised controlled trials in oncology Lancet Oncol. 2016; 17:e560-e567 2. Agrawal, S. ∙ Arora, S. ∙ Amiri-Kordestani, L. ...

Keywords NIZ985 heterodimeric IL-15 Spartalizumab Tislelizumab Phase I/Ib clinical trial Solid tumors Get full text access Log in, subscribe or purchase for full access. Data availability statement Data are available on reasonable request. Novartis will not provide access to patient-level data, if there is a reasonable likelihood that individual patients could be reidentified.

Keywords NIZ985 heterodimeric IL-15 Spartalizumab Tislelizumab Phase I/Ib clinical trial Solid tumors Get full text access Log in, subscribe or purchase for full access. Data availability statement Data are available on reasonable request. Novartis will not provide access to patient-level data, if there is a reasonable likelihood that individual patients could be reidentified.

Keywords trametinib NRAS codon specificity tumor-agnostic precision medicine DRUP Get full text access Log in, subscribe or purchase for full access. References 1. Bendell, J.C. ∙ Javle, M. ∙ Bekaii-Saab, T.S. ... A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor British Journal of Cancer. 2017; 116(5):575-583 2. Borthakur, G. ∙ Popplewell, L. ∙ Boyiadzis, M. ...

Get full text access Log in, subscribe or purchase for full access. References 1. Sikkema, B.J. ∙ Veerman, M. ∙ Hoop, Oomen-de ... A-MC. Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC Eur J Cancer. 2026; 240, 116742 2. Wang, Y.X. ∙ Feige, P. ∙ Brun, C.E. ... EGFR-Aurka signaling rescues polarity and regeneration defects in dystrophin-deficient muscle stem cells by increasing asymmetric divisions Cell Stem Cell.

Keywords Larotrectinib NTRK fusion pediatric oncology real-world data infantile fibrosarcoma CNS tumors soft tissue sarcoma precision oncology Get full text access Log in, subscribe or purchase for full access. References 1. Drilon, A. ∙ Laetsch, T.W. ∙ Kummar, S. ... Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children N Engl J Med. 2018 Feb 22; 378(8):731-739 PMID: 29466156; PMCID: PMC5857389. 2. Hong, D.S. ∙ DuBois, S.G. ∙ Kummar, S. ...

Keywords interstitial lung disease first-line immune checkpoint inhibitor non-small cell lung cancer high-resolution computed tomography pneumonitis overall survival 1 Introduction Immune checkpoint inhibitors (ICIs) are standard treatments for patients with advanced or recurrent non-small cell lung cancer (NSCLC) without actionable driver gene alterations, such as epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.

Keywords In-transit metastases unresectable melanoma stage III-IV melanoma immune checkpoint inhibitors talimogene laherparepvec T-VEC BRAF/MEK inhibition regional therapy immunotherapy 1 Introduction In-transit metastases (ITM) in melanoma are defined as cutaneous and/or subcutaneous metastases located more than 2 cm from the primary melanoma but not beyond the first regional lymph node.